Assessment of immunosuppression by serum inhibition of alloreaction and measurement of cyclosporin A (CyA) serum levels in kidney graft recipients under CyA

1990 ◽  
Vol 3 (4) ◽  
pp. 189-194
Author(s):  
D. Chabannes ◽  
L. Vernillet ◽  
D. Cantarovich ◽  
H. Humbert ◽  
H. Vie ◽  
...  
1991 ◽  
Vol 4 (1) ◽  
pp. 235-238 ◽  
Author(s):  
R. Baatard ◽  
J. Dantal ◽  
M. Hourmant ◽  
D. Cantarovich ◽  
A. Cesbron ◽  
...  

2009 ◽  
Vol 23 (5) ◽  
pp. 465-475 ◽  
Author(s):  
Mario Rotondi ◽  
Giuseppe Stefano Netti ◽  
Elena Lazzeri ◽  
Giovanni Stallone ◽  
Elisabetta Bertoni ◽  
...  

1988 ◽  
Vol 14 (1) ◽  
pp. 60-65
Author(s):  
YOUICHI HASEGAWA ◽  
HISAYOSHI SUGIHARA ◽  
AKIRA TAKAHASHI ◽  
HIROSHI HISHIDA ◽  
YASUTAKA SAKAMOTO ◽  
...  

Blood ◽  
1983 ◽  
Vol 61 (2) ◽  
pp. 318-325 ◽  
Author(s):  
PJ Tutschka ◽  
WE Beschorner ◽  
AD Hess ◽  
GW Santos

Cyclosporin-A (CsA) was given to 22 patients who received allogeneic bone marrow transplants as therapy for aplastic anemia and hematologic malignancies. The drug was given daily for 180 days starting with the day of marrow infusion. Engraftment was not impaired and myelotoxicity was not observed. Cutaneous graft-versus-host disease (GVHD) developed in five patients and all either spontaneously resolved or promptly responded to therapy with steroids. Five patients developed systemic GVHD and all responded to therapy with steroids, but only two survived. Interstitial pneumonia was seen in six patients and was fatal in all of them. Liver function abnormalities were seen in 14 patients but could not positively be correlated with CsA administration. Renal function abnormalities were seen in 17 patients. Amphotericin-B therapy contributed significantly to the renal failure. Serum levels of CsA, measured by radioimmunoassay, could not be correlated with the presence of liver or renal function abnormalities. Overall survival so far has been 50.0%. Second malignancies were not observed, but one patient relapsed with leukemia at 343 days.


Blood ◽  
2001 ◽  
Vol 97 (4) ◽  
pp. 1027-1034 ◽  
Author(s):  
Elena Chklovskaia ◽  
Catherine Nissen ◽  
Lukas Landmann ◽  
Christoph Rahner ◽  
Otmar Pfister ◽  
...  

Abstract The flt3 ligand (FL) is a growth and differentiation factor for primitive hematopoietic precursors, dendritic cells, and natural killer cells. Human T lymphocytes express FL constitutively, but the cytokine is retained intracellularly within the Golgi complex. FL is mobilized from the cytoplasmic stores and its serum levels are massively increased during the period of bone marrow aplasia after stem cell transplantation (SCT). Signals that trigger the release of FL by T cells remain unknown. This study shows that interleukin (IL)-2, IL-4, IL-7, and IL-15, acting through a common receptor γ chain (γc), but not cytokines interacting with other receptor families, are efficient inducers of cell surface expression of membrane-bound FL (mFL) and secretion of soluble FL (sFL) by human peripheral blood T lymphocytes. The γc-mediated signaling up-regulated FL in a T-cell receptor-independent manner. IL-2 and IL-7 stimulated both FL messenger RNA (mRNA) expression and translocation of FL protein to the cell surface. Cyclosporin A (CsA) inhibited γc-mediated trafficking of FL at the level of transition from the Golgi to the trans-Golgi network. Accordingly, serum levels of sFL and expression of mFL by T cells of CsA-treated recipients of stem cell allografts were reduced approximately 2-fold (P < .01) compared to patients receiving autologous grafts. The conclusion is that FL expression is controlled by γc receptor signaling and that CsA interferes with FL release by T cells. The link between γc-dependent T-cell activation and FL expression might be important for T-cell effector functions in graft acceptance and antitumor immunity after SCT.


1982 ◽  
Vol 4 (3) ◽  
pp. 84-86 ◽  
Author(s):  
E. Abisch ◽  
T. Beveridge ◽  
A. Gratwohl ◽  
W. Niederberger ◽  
K. Nussbaumer ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document